Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats metastatic breast cancer in postmenopausal women with estrogen-receptor positive…. Sold as Fareston. Every FDA application for this active ingredient: 1 branded and 2 generic.
As of Nov 14, 2026, FDA lists 3 applications for Toremifene Citrate (sold as Fareston), first approved May 29, 1997, with 0 new uses approved and 0 published complete response letters.
First approved: May 29, 1997
Applications: 3
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $796K
First approved in the EU: Feb 14, 1996
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Toremifene Citrate
Part D
$796K
-9%
158
Fareston
Part D
$0K
-100%
0
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
TOREMIFENE CITRATE 60 MG TAB: $20.41 per unitGeneric · -15% in a year
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Kyowa Kirin